Search - tctmd.com

Displaying 121 - 140 of 286

Sort: Relevancy | Date

Presentation TCT 2019

Study Design Considerations for HBR Patients and DES Platforms: FDA View

Presenter: Adrian Magee

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

Presentation TCT 2019

Ultrathin Orsiro: Where It Can Go

Presenter: Steven Yakubov

September 26, 2019

Presentation TCT 2019

FDA Pivotal Clinical Trial Design and Beyond

Presenter: Ori Ben-Yehuda

September 26, 2019

Presentation TCT 2019

Use of Sirolimus-Coated Balloon (MagicTouch) in Coronary Intervention: Data and Case Examples From a Real-World Population

Presenter: Sandeep Basavarajaiah

September 26, 2019

Presentation TCT 2019

A Personal Perspective: Why I Choose Orsiro in STEMI

Presenter: Juan Fernando Iglesias

September 26, 2019

Presentation TCT 2019

Real-World Data From EASTBOURNE to TRANSFORM Trials

Presenter: Bernardo Cortese

September 26, 2019

Presentation TCT 2019

First Experience With FDA-Approved Orsiro in the USA

Presenter: Farouc Jaffer

September 26, 2019

Presentation TCT 2019

First-in-Man: Brazil ISR Experience With Angiographic and IVUS Results

Presenter: Alexandre Abizaid

September 26, 2019

Presentation TCT 2019

Why SEB Should Be Safer: Insights From Preclinical Study

Presenter: Aloke Finn

September 26, 2019

Presentation TCT 2019

Delivering Evidence

Presenter: James Hermiller

September 26, 2019

Presentation TCT 2019

Concept of MagicTouch

Presenter: Ajay Kirtane

September 26, 2019

Presentation TCT 2019

MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Presenter: Ken Kozuma

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs. a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease

Presenter: Robert-Jan Van Geuns

September 26, 2019

Presentation TCT 2019

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

The Low-Bleeding Risk Patient: Should DAPT be Tailored Based on Clinical Presentation, Anatomic Complexity or DES Type?

Presenter: Ajay Kirtane

September 26, 2019

Presentation TCT 2019

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Primer on Metallic Stents Developed in India

Presenter: Upendra Kaul

September 26, 2019

Advertisement

Study Design Considerations for HBR Patients and DES Platforms: FDA View

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Ultrathin Orsiro: Where It Can Go

FDA Pivotal Clinical Trial Design and Beyond

Use of Sirolimus-Coated Balloon (MagicTouch) in Coronary Intervention: Data and Case Examples From a Real-World Population

A Personal Perspective: Why I Choose Orsiro in STEMI

Real-World Data From EASTBOURNE to TRANSFORM Trials

First Experience With FDA-Approved Orsiro in the USA

First-in-Man: Brazil ISR Experience With Angiographic and IVUS Results

Why SEB Should Be Safer: Insights From Preclinical Study

Delivering Evidence

Concept of MagicTouch

MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs. a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

The Low-Bleeding Risk Patient: Should DAPT be Tailored Based on Clinical Presentation, Anatomic Complexity or DES Type?

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Primer on Metallic Stents Developed in India

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content